uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences:

uniQure to Participate in Multiple Upcoming Industry Conferences in December

~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announced positive top-line data from a pivotal Phase 3 study, dubbed HOPE-B, that evaluated its investigational adeno-associated virus five-based gene-therapy candidate etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B.

UniQure Rallies On Positive Late-Stage Data For Hemophilia B Gene Therapy

Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy. The company says the drug improved clotting protein at 26 weeks.

Uniqure Hits Pay Dirt In Gene Therapy And The Biotech Stock Bounds Higher

~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~

uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation and three poster presentations, will be delivered at the 62nd American Society of Hematology (ASH) Annual Meeting, which will be held December 5-8 as a virtual event.

uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that members of uniQure's management team including Matt Kapusta, chief executive officer, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in November:

uniQure to Participate in Multiple Upcoming Industry Conferences in November

~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~

uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

Blueprint Medicines

AnaptysBio

Dicerna Pharmaceuticals

Spero Therapeutics

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in biotech research and investments, which included 15 years working at Mark Lampert's Biotechnology Value Fund, to seek out mispriced small-cap companies in the biotech sector. The fund's assets under management surpassed $500 million as of August 2020.

5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting 30,000 to generate strong returns. However, as we know, big investors usually buy stocks with strong fundamentals that can deliver gains both in bull and bear markets, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Uniqure NV (NASDAQ:QURE).

Were Hedge Funds Right About Piling Into Uniqure NV (QURE)?

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth

LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. The ongoing patient enrollment follows a meeting last month of the trial’s independent Data Safety Monitoring Board (DSMB) to review 90-day follow-up data from the first two patients. The DSMB observed no significant safety concerns to prevent further dosing.  The Phase I/II study is a double-blinded, randomized and controlled clinical trial being conducted in the United States. A total of four patients have been enrolled in the study thus far, including two patients treated with AMT-130 and two patients who received imitation surgery.

uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

REGENXBIO

Sarepta Therapeutics

Voyager Therapeutics

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays.

Gene Therapy Stocks Continue To Underperform. Are They Worth A Look?

~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~ ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~

uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

Implied Volatility Surging for uniQure (QURE) Stock Options

Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors

uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development

A Quick Investment Idea On uniQure

~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~

uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress

UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agreement licenses the rights for a promising hemophilia B gene therapy.

uniQure Inks $2 Billion Licensing Deal With CSL Behring

Shares of UniQure QURE, -7.13% tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring CSL, +0.56% would acquire exclusive commercialization rights to its gene-therapy program.

UniQure's shares fall on licensing deal for gene therapy

Biotech company Uniqure inked a $2 billion licensing deal for its hemophilia B gene therapy late Wednesday. But shares of QURE stock collapsed in response in after-hours trading.

Is A Merger Out Of Reach After This Biotech Inked A $2 Billion Licensing Deal?

~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~

uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

Sanofi

Did Sanofi Free Up Cash To Acquire uniQure?

~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ ~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~

News for uniQure Stock (QURE)